Trial Profile
A Multi-center, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects With Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Feb 2021
Price :
$35
*
At a glance
- Drugs Fluocinolone acetonide (Primary)
- Indications Posterior uveitis
- Focus Registrational; Therapeutic Use
- Sponsors EyePoint Pharmaceuticals
- 16 Nov 2020 Results presented in an EyePoint Pharmaceuticals media release.
- 16 Nov 2020 According to an EyePoint Pharmaceuticals media release, data from this trial were presented at American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting.
- 10 Nov 2020 According to an EyePoint Pharmaceuticals media release, data from this trial will be presented at American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting.